Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company usually posts poor financials for mid or long term investments.
Strengths
  • The share is getting closer to its long-term support in weekly data, at CHF 2.63, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the CHF 2.59 support.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • Low profitability weakens the company.
  • The company's earnings releases usually do not meet expectations.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 6.02 CHF
Ratings chart
Sector Specialty & Advanced Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
SANTHERA PHARMACEUTICALS HO..-74.87%61
MERCK KGAA30.42%72 586
ZHANGZHOU PIENTZEHUANG PHAR..103.99%20 668
KYOWA KIRIN CO., LTD.11.39%14 828
BETTA PHARMACEUTICALS CO., ..47.90%5 986
YUHAN CORPORATION38.48%3 565
RECIPHARM AB (PUBL)29.29%2 026
SUPERNUS PHARMACEUTICALS, I..-8.26%1 146
INDIVIOR161.54%1 009
KISSEI PHARMACEUTICAL CO., ..-32.40%949
CALLIDITAS THERAPEUTICS AB ..90.49%853
DONG-A ST CO., LTD.-27.31%668
NICHI-IKO PHARMACEUTICAL CO..-26.01%621
KNIGHT THERAPEUTICS INC.-30.08%536
CHONG KUN DANG HOLDINGS COR..7.43%498
MAYNE PHARMA GROUP LIMITED-19.54%437
More Results
Financials
Sales 2020 14,6 M 16,4 M 16,4 M
Net income 2020 -55,3 M -62,0 M -62,0 M
Net Debt 2020 - - -
P/E ratio 2020 -0,90x
Yield 2020 -
Capitalization 54,1 M 60,7 M 60,7 M
Capi. / Sales 2020 3,70x
EV / Sales 2021 1,92x
Nbr of Employees 113
Free-Float 86,1%
Upcoming event on SANTHERA PHARMACEUTICALS HOLDING AG
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating -
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability -
P/E ratio -
Potential
Yield -
Consensus -
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes